3q27.2-qter deletion syndromes feature an overlapping set of terminal and interstitial deletions with variable congenital malformations. Diamond-Blackfan anemia (DBA) is etiologically heterogeneous disorder in which one cause is dominant mutations of the RPL35A gene on 3q29. We report a child with a 3q27.2-qter deletion that contains the RPL35A gene.
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She had clinical and laboratory features consistent with DBA and as well, an unexplained immunodeficiency disorder. Given these unusual findings, we reviewed other patients in the literature with overlapping genomic deletions. In addition, we evaluated our patient for the immunodeficiency disorder, RIDDLE syndrome, due to recessive mutations in the RNF168 gene on 3q29. A PubMed search for case reports of 3q27.2-qter overlapping deletions was performed. To determine if RPL35A was in the deletion region, the chromosomal regions reported were mapped to genomic regions using the UCSC Genome Browser. We identified 85 overlapping deletions, of which six included the RPL35A gene and all should be had DBA.
Interestingly, none of the reported cases had immunodeficiency. To evaluate RIDDLE syndrome (radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties), we sequenced the remaining RNF168 gene and examined her fibroblast culture for a DNA double strand break repair deficiency. These results were normal, indicating that the immunodeficiency is unlikely to result from a RNF168 deficiency. We show that RPL35A haploinsufficiency is a cause of DBA and we report a novel case with 3q27.2-qter deletion and immunodeficiency. The etiology for the immunodeficiency remains unsolved and could be caused by an unknown gene effect or consequent to the DBA phenotype.
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3q27.2-qter deletion syndromes feature an overlapping set of terminal and interstitial deletions with variable congenital malformations, dysmorphic features, and clinical manifestations. DBA (MIM # 105650) is a rare dominant congenital blood disorder that often manifests in the first 2 years of life with normochromic, macrocytic anemia, and selective deficiency of red cell precursors due to absent erythroid progenitors in the bone marrow. The diagnosis of DBA is based on clinical and laboratory diagnostic criteria, that include: (1) age younger than 1-year; (2) macrocytic anemia with no other significant cytopenias; (3) reticulocytopenia; and (4) normal marrow cellularity with a paucity of erythroid precursors.
Supporting major criteria include: (1) a gene mutation described in classical DBA and (2) a positive family history. Supporting minor criteria include: (1) increased erythrocyte adenosine deaminase activity (eADA); (2) congenital anomalies described in classical DBA; (3) elevated hemoglobin F; and (4) an absence of evidence of other bone marrow failure syndromes (Da Costa et al., 2010; Lipton & Ellis, 2010; Vlachos et al., 2008) . Currently, DBA is due to defects causing birth, she presented with failure to thrive that led to a diagnosis of coarctation of the aorta and severe mitral stenosis, which was surgically repaired. At this time, there was severe anemia with hemoglobin of <56 g/L which required red blood cell transfusions. In addition, she was suspected to have Crohn's disease, based on both clinical and histological evidence; for this she was treated with steroids which were tapered and stopped in the first year of life without relapse. The hemoglobin level was stable during the period of steroid treatment. Furthermore, she had gastro-esophageal reflux disease which eventually required a Nissen fundoplication and gastrostomy because of insufficient oral intake and weight loss. In her first few years of life, she had multiple upper respiratory tract infections and pneumonias, the latter required multiple hospital admissions. At 5 years of age, she was started on weekly subcutaneous immunoglobulin for low immunoglobulin titers and this treatment eliminated further pneumonias. In term of development, she has motor and language delays. She started to walk and speak at around 3 years of age. She has expressive language delay with good receptive language skills. At 9 years, she has 15 single words. Her fine motor and social skills were age-appropriate. 
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We identified 85 patients from the literature with deletions overlapping 3q27.2-qter (Table 1) . Six cases overlapped with the RPL35A region and had DBA. All cases showed clinical manifestations that includes craniofacial abnormalities, developmental delay, growth deficiencies, and variable congenital malformations that likely correspond to the associated genomic deletion. However, there were no patients reported with immunodeficiency.
For the cases with DBA (Table 1) , two were reported by (Farrar et al., 2008) , one with a de novo 3q28-qter deletion and another with a 3q29 deletion. The first patient had anemia that responded to steroid treatment. He developed neutropenia, and had a bone marrow biopsy done that showed decreased myeloid maturation with mild dysplasia. He remained steroid dependent and subsequently developed persistent leukopenia. The second patient presented at 7 weeks of life with macrocytic anemia, reticulocytopenia, increased eADA activity, and hemoglobin F levels and responded to steroid treatment.
In these two patients, decreased expression of RPL35A transcripts was confirmed by quantitative RT-PCR (Farrar et al., 2008 All of these cases were identified on the basis of DBA features. In the Glassford report, it is not clear if any of these patients were previously reported.
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Although the Farrar et al. (2008) patient above developed neutropenia and leukopenia, the etiology was obscured by the concomitant steroid use. However, our patient was not on steroids at the time the immunodeficiency presented. We considered whether our patient had an autosomal recessive cause of immunodeficiency, involving a deleted gene together with a second mutation on the remaining gene. We reviewed genes in this region (76 OMIM genes) and identified only RIDDLE syndrome, which is caused by recessive mutations in the RNF168 gene at 3q29. The syndrome is associated with low immunoglobulin levels, short stature and developmental delay which were exhibited by our patient (Stewart et al., 2007) . We sequenced the remaining RNF168 gene and examined our patient's fibroblasts for an inability to delocalize DSB repair proteins to sites of ionizing radiation ( . Dominant mutations in RPL35A account for (∼3%) of DBA cases (Farrar & Dahl, 2011) .
We have shown that complete deletion of RPL35A can also cause DBA syndrome and was present in our patient as well as six other patients in the literature (Farrar et al., 2008; Kuramitsu et al., 2012; Quarello et al., 2012) . The cases from the literature were identified by virtue of the patient being recognized with DBA, thus showing that complete gene deletions can underlie this disorder. In our patient, she was recognized first as having a 3q27.2-qter deletion, which then facilitated the correct diagnosis of her anemia. Considering the frequent use of aCGH as a diagnostic tool, these cases illustrate the co-occurrence of RPL35A deletions and DBA. We did not find any instances of an RPL35A deletion without the co-occurrence of DBA.
Although the cause of the DBA is clarified, the etiology of the immunodeficiency phenotype in our patient remains unsolved. The immune dysregulation in this case affected B-cell immunity most, requiring weekly subcutaneous IgRT, and to a lesser extent affecting in the relatives. When this was adjusted to variables known to influence the immune response, no significant differences between the two groups were observed. Recently, a patient was reported with a clinical diagnosis of DBA and common variable immunodeficiency without a definite cause identified for the immune deficiency (Khan et al., 2011) .
Finally, there is the possibility that this child has an additional diagnosis that has not yet been recognized, and could be investigated by whole genome/exome sequencing. Thus, the relationship between DBA and immunodeficiency remains unresolved and we contribute another case in which an immunodeficiency might be an underlying feature of the DBA itself.
In conclusion, we have presented a 9-year-old girl with a novel de novo 12.594 Mb deletion syndrome (3q27.2-qter). In addition to DBA due to RPL35A haploinsufficiency causing the DBA phenotype manifestation, she had an unexplained immunodeficiency. We propose that this is secondary to an unknown gene effect, or to the DBA phenotype itself. Finally, applying DBA diagnostic criteria is warranted with those patients who carry 3q
terminal deletions that overlap with RPL35A genomic region.
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